Miflonid Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonid Breezhaler, is a glucocorticoid corticosteroid presented as an inhalation powder for inhalation use. It reduces airway inflammation and is indicated for the long‑term management of asthma and chronic obstructive pulmonary disease (COPD) in adults and children when prescribed by a healthcare professional.

GNH USA supplies Miflonid Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet EU regulatory standards with reliable logistics and regulatory support for cross‑border distribution.

Miflonid Breezhaler (budesonide) is a glucocorticoid inhaled to control airway inflammation in respiratory disease. - Asthma: improves symptom control and reduces frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps maintain lung function. - Bronchial hyperresponsiveness: reduces airway reactivity to triggers.

Inhaled budesonide may cause a range of adverse reactions, most of which are mild and related to the local airway or systemic exposure.

Common Side Effects: - Hoarseness or voice change. - Oral thrush (candidiasis). - Cough or throat irritation. - Headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with long‑term high‑dose use. - Severe allergic reaction (anaphylaxis, angioedema).

Before prescribing Miflonid Breezhaler, clinicians should consider several safety precautions. - Assess infection: screen for active respiratory infections before initiating therapy. - Monitor growth: children on long‑term inhaled corticosteroids should have growth monitored regularly. - Evaluate bone health: prolonged high‑dose use may affect bone mineral density; consider calcium/vitamin D supplementation. - Use spacer: recommend a spacer device and mouth rinsing after inhalation to reduce oral candidiasis. - Review drug interactions: check for concomitant use of strong CYP3A4 inhibitors that may increase systemic exposure. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Budesonide can interact with other medicines that affect its metabolism or enhance corticosteroid effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may markedly increase systemic budesonide levels, raising risk of adrenal suppression. - Systemic corticosteroids: concurrent use can lead to additive glucocorticoid effects and increased side‑effect risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole) may modestly raise budesonide exposure. - Protease inhibitors such as ritonavir can increase plasma concentrations. - Diuretics (e.g., furosemide) may potentiate hypokalemia when combined with systemic corticosteroid effects.